DK1023903T3 - Anvendelse af levende, svækkede bakterier til fremstilling af en submukös vaccine - Google Patents

Anvendelse af levende, svækkede bakterier til fremstilling af en submukös vaccine

Info

Publication number
DK1023903T3
DK1023903T3 DK00200216T DK00200216T DK1023903T3 DK 1023903 T3 DK1023903 T3 DK 1023903T3 DK 00200216 T DK00200216 T DK 00200216T DK 00200216 T DK00200216 T DK 00200216T DK 1023903 T3 DK1023903 T3 DK 1023903T3
Authority
DK
Denmark
Prior art keywords
vaccine
submucous
live attenuated
produce
attenuated bacteria
Prior art date
Application number
DK00200216T
Other languages
Danish (da)
English (en)
Inventor
Antonius Arnoldus Chris Jacobs
Danny Goovaerts
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of DK1023903T3 publication Critical patent/DK1023903T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/82—Viral vaccine for equine species, e.g. horses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK00200216T 1999-01-26 2000-01-20 Anvendelse af levende, svækkede bakterier til fremstilling af en submukös vaccine DK1023903T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99200202 1999-01-26

Publications (1)

Publication Number Publication Date
DK1023903T3 true DK1023903T3 (da) 2004-05-10

Family

ID=8239828

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00200216T DK1023903T3 (da) 1999-01-26 2000-01-20 Anvendelse af levende, svækkede bakterier til fremstilling af en submukös vaccine

Country Status (10)

Country Link
US (2) US20040120970A1 (de)
EP (1) EP1023903B1 (de)
JP (1) JP4339978B2 (de)
AT (1) ATE257713T1 (de)
AU (1) AU761515B2 (de)
CA (1) CA2296965A1 (de)
DE (1) DE60007668T2 (de)
DK (1) DK1023903T3 (de)
ES (1) ES2214217T3 (de)
PT (1) PT1023903E (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
GB0315323D0 (en) * 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
EP3895737A1 (de) * 2007-06-29 2021-10-20 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Verfahren zur fixierung und expression einer physiologisch aktiven substanz
GB0801326D0 (en) * 2008-01-24 2008-03-05 Animal Health Trust Vaccines
KR101210082B1 (ko) * 2010-10-15 2012-12-07 주식회사 동방 돼지 다발성 장막염 예방용 백신 조성물 및 그 제조방법
KR101694676B1 (ko) * 2015-12-10 2017-01-10 우진 비앤지 주식회사 말 선역 질병원인 국내 분리 스트렙토코커스 이콰이 균주 및 이를 포함하는 백신
WO2020032232A1 (ja) 2018-08-10 2020-02-13 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 バクテリオファージ剤
CN112973157A (zh) * 2021-02-04 2021-06-18 广西田东锦盛化工有限公司 一种用于氯碱生产的盐水浓缩装置
CN113244664A (zh) * 2021-05-12 2021-08-13 伍俊雄 一种用于疫苗破乳及分离的装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2033223B (en) * 1978-09-01 1983-09-14 Secr Social Service Brit Antigen fromstreptococcus mutans for protection against dental caries
JPS6037734B2 (ja) 1978-10-12 1985-08-28 住友電気工業株式会社 管状臓器補綴材及びその製造方法
EP0068660B1 (de) * 1981-06-19 1985-04-17 Secretary of State for Social Services in Her Britannic Majesty's Gov. of the U.K. of Great Britain and Northern Ireland Schutz gegen Karies
IE940698L (en) * 1984-04-05 1985-10-05 Univ Missouri Vaccine and serum for endotoxin associated disease and method of preparing same as well as to methods of immunization and treatment of such disease and to a detoxified endotoxin and bacterial mutant
AR241545A1 (es) * 1985-07-12 1992-08-31 Cornell Res Foundation Inc Un metodo para preparar una cepa de s. equi avirulenta a.t.c.c. 53186 para equinos.
BE1008103A3 (fr) 1994-04-22 1996-01-16 Pantochim Sa Procede de preparation de catalyseurs au vanadium et phosphore et leur utilisation pour la production d'anhydride maleique.
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
US5895756A (en) * 1997-04-11 1999-04-20 The Board Of Trustees Of The University Of Texas System Non-antibiotic system for selection of recombinant mycobacteria
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
US6682745B1 (en) * 1998-07-28 2004-01-27 Christiaan Antonius Arnoldus Jacobs Use of bacterium for manufacture of a vaccine
US6344201B1 (en) * 1998-03-31 2002-02-05 Anthony T. Maurelli Methods of identifying bacterial genes that are incompatible with bacterial pathogenicity, and the use of such genes, such as cadA, to reduce pathogenicity in a bacteria or to combat pathogenic bacterial infections

Also Published As

Publication number Publication date
JP4339978B2 (ja) 2009-10-07
JP2000309542A (ja) 2000-11-07
DE60007668T2 (de) 2004-12-02
PT1023903E (pt) 2004-04-30
US20110123571A1 (en) 2011-05-26
AU1355700A (en) 2000-07-27
EP1023903B1 (de) 2004-01-14
US8084040B2 (en) 2011-12-27
DE60007668D1 (de) 2004-02-19
AU761515B2 (en) 2003-06-05
ES2214217T3 (es) 2004-09-16
EP1023903A1 (de) 2000-08-02
CA2296965A1 (en) 2000-07-26
ATE257713T1 (de) 2004-01-15
US20040120970A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
PL363168A1 (pl) Cyklopentanole, kompozycje zawierające takie związki i sposoby leczenia
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
DK1385515T3 (da) Spiropyrazole forbindelser
PT1379520E (pt) Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b
HN1999000125A (es) Nuevos derivados sustituidos del pirazol
DE60035639D1 (de) Hydroxydiphenyletherverbindungen
ES2172864T3 (es) 2-metoxibenzofenonas fungicidas.
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
CL2004001085A1 (es) Compuestos derivados de quinolil propil piperidina, procedimiento de preparacion; compuesto intermediario; composicion farmaceutica, utiles como agentes microbianos.
DK1023903T3 (da) Anvendelse af levende, svækkede bakterier til fremstilling af en submukös vaccine
TR199901017A2 (xx) B�cek ilac� terkibi.
PT1204658E (pt) Agonistas benzofurilpiperazina de serotonina
DE60006825D1 (de) Serotonerge benzofurane
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
DK1206452T3 (da) Fremgangsmåde til fremstilling af benzoperhydro-isoindolforbindelser
ECSP003761A (es) Compuestos heterociclicos sililados
IT1319686B1 (it) Procedimento di preparazione di citalopram.
ATE526835T1 (de) Orale zusammensetzung enthaltend difructoseanhydrid
DK1280752T3 (da) Fremgangsmåde til fremstilling af 2-alkyl-3-chlorphenoler
ATE249204T1 (de) Spray, enthaltend ubichinon qn
PE20001466A1 (es) Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas como bloqueadores del canal de sodio
BR0113202A (pt) Compostos de trioxepano
SE9901340D0 (sv) Novel process
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων